The Journal of infectious diseases

[1] Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

[2] genetic variation and drug resistance mutation of influenza virus during 2013-2014 in beijing, china: a report of 37 cases

[3] Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

[4] Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

[5] Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

[6] Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity

[7] dual acting neuraminidase inhibitors open new opportunities to disrupt the lethal synergism between streptococcus pneumoniae and influenza virus

[8] Design, synthesis and biological evaluation of honokiol derivatives as influenza neuraminidase inhibitors.

[9] Treatment of influenza with neuraminidase inhibitors: virological implications